Inhibikase Therapeutics (NYSE:IKT – Get Free Report) and Senti Biosciences (NASDAQ:SNTI – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends. Institutional and Insider Ownership 14.0% of Inhibikase […]
Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT – Get Free Report) dropped 12.4% during trading on Thursday . The company traded as low as $2.05 and last traded at $2.05. Approximately 53,482 shares were traded during mid-day trading, an increase of 23% from the average daily volume of 43,403 shares. The stock had previously closed at […]
Inhibikase Therapeutics (NYSE:IKT – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $27.00 price objective on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q3 2023 earnings at ($1.12) EPS, Q4 2023 earnings at ($1.17) EPS, FY2023 […]
Inhibikase Therapeutics (NYSE:IKT – Get Free Report) is set to announce its earnings results after the market closes on Monday, August 14th. Analysts expect the company to announce earnings of ($0.92) per share for the quarter. Inhibikase Therapeutics (NYSE:IKT – Get Free Report) last announced its quarterly earnings data on Monday, May 15th. The company […]
Inhibikase Therapeutics, Inc. (NYSE:IKT – Get Rating) – Stock analysts at HC Wainwright raised their Q2 2023 earnings per share estimates for shares of Inhibikase Therapeutics in a research report issued on Tuesday, May 16th. HC Wainwright analyst E. White now forecasts that the company will earn ($0.15) per share for the quarter, up from […]